Dankzij de gegevens van patiënten in het GLAS-cohort hebben we inmiddels een groot aantal publicaties geschreven. Hieronder ziet u hier een overzicht van. Mocht u interesse hebben om een van deze artikelen te lezen mag u altijd even mailen. Wij kunnen u dit (zonder kosten) toesturen.
Internationaal (geschreven in het Engels):
Patient’s perspective on axial pain in relation to inflammation and structural damage in a large cohort of axial spondyloarthritis patients. A. Kampman, F. Wink, D, Paap, M. Carbo, M. Siderius, S. Kieskamp, F. Maas, A. Spoorenberg, S. Arends. Arthritis Care Res (Hoboken) 2023. Online ahead of print.
Serum levels of bone turnover markers including calculation of Z-scores: data from a Dutch healthy reference cohort. M. Siderius, S. Arends, A. Muller Kobold, L. Wagenmakers, K. Koerts, A. Spoorenberg, E. van der Veer. Bone Rep. 2023;19:101724.
High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis. L. de Wolff, S. Arends, E. Brouwer, H. Bootsma, A. Spoorenberg. Arthritis Res Ther. 2023;25(1):202.
Psoriasis seems often underdiagnosed in patient with axial spondyloarthritis. A. Rondags, L. van Marle, B. Horváth, F.R. Wink, S. Arends, A. Spoorenberg. Arthritis Res Ther. 2023;25(1):145.
Patients’ Needs Concerning Patient Education in Axial Spondyloarthritis: A Qualitative Study. Y.M. van der Kraan, D. Paap, N. Lennips, E.C.A. Veenstra, F.R. Wink, S.C. Kieskamp, A. Spoorenberg. Rheumatol Ther. 2023;10(5):1349-68.
Stable bone turnover markers corrected for age and gender during the first year of secukinumab treatment in ankylosing spondylitis patients. M. Siderius, S. Arends, F. Wink, F. Kroese, A. Spoorenberg. Clin Exp Rheumatol. 2023;41(9):1942-3
After an initial balance favoring collagen formation and mineralization, bone turnover markers return to pre-treatment levels during long-term TNF-α inhibition in patients with ankylosing spondylitis. M. Siderius, A. Spoorenberg, F.G.M. Kroese, E. van der Veer, S. Arends. PLoS One. 2023;18(3):e0283579.
Mucosal-associated invariant T cells in patients with axial spondyloarthritis. R.G. Van Der Meer, A. Spoorenberg, E. Brouwer, B. Doornbos-Van Der Meer, A.M.H. Boots, S. Arends, W.H. Abdulahad. Frontiers in Immunology. 2023;14:1128270.
Differences in characteristics, health status and fulfillment of exercise recommendations between axial spondyloarthritis patients with and without supervised group exercise. B. Hilberdink, M. Carbo, D. Paap, S. Arends, T. Vliet Vlieland, F. van der Giesen, A. Spoorenberg, S. van Weely. Semin Arthritis Rheum. 2022;55:152035.
Baseline serum biomarkers of inflammation, bone turnover and adipokines predict spinal radiographic progression in ankylosing spondylitis patients on TNF inhibitor therapy. J. Rademacher, M. Siderius, L. Gellert, F. Wink, M. Verba, F. Maas, L.M. Tietz, D. Poddubnyy, A. Spoorenberg, S. Arends. Semin Arthritis Rheum. 2022;53:151974.
Central sensitization has a major impact on quality of life in patients with axial spondyloarthritis. S.C. Kieskamp, D. Paap, M.J.G. Carbo, F. Wink, R. Bos, H. Bootsma, S. Arends, A. Spoorenberg. Semin Arthritis Rheum. 2022;52:151933.
Change in disease activity is associated with TNF-α inhibitor serum levels in patients with axial spondyloarthritis in daily clinical practice. L. de Wolff, F.R. Wink, H. Bootsma, S. Arends, A. Spoorenberg. Clin Exp Rheumatol. 2022;40(3):489-494.
Extra-skeletal manifestations in axial spondyloarthritis are associated with worse clinical outcome despite the use of TNF blocking therapy. R. van der Meer, S. Arends, S. Kruidhof, R. Bos, H. Bootsma, F. Wink, A. Spoorenberg. J Rheumatol. 2022;49(2):157-164.
B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis. R. Wilbrink, A. Spoorenberg, G.J.M.P. Verstappen, F.G.M. Kroese. Int J Mol Sci. 2021;22(24):13325.
The mSQUASH; a valid, reliable and responsive questionnaire for daily physical activity in patients with axial spondyloarthritis. M.J. Carbo, D. Paap, F. Maas, A.J. Baron, L.C. van Overbeeke, M. Siderius, H. Bootsma, F. Wink, S. Arends, A. Spoorenberg. Semin Arthritis Rheum. 2021;51(4):719-727.
CD27-CD38lowCD21low B-Cells Are Increased in Axial Spondyloarthritis. R. Wilbrink, A. Spoorenberg, S. Arends, K.S.M. van der Geest, E. Brouwer, H. Bootsma, F.G.M. Kroese, G.M. Verstappen. Front Immunol. 2021;12:686273.
Central sensitization and disease perceptions should be taken into account when interpreting disease activity in patients axial spondyloarthritis. S. Kieskamp, D. Paap, M.J.G. Carbo, F. Wink, R. Bos, H. Bootsma, S. Arends, A. Spoorenberg. Rheumatology (Oxford). 2021;60(10):4476-4485
Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Molto, C. Lopez-Medina, F. van den Bosch, A. Boonen, C. Webers, E. Dernis, F. van Gaalen, M. Soubrier, P. Claudepierre, A. Baillet, M. Starsman-Kool, A. Spoorenberg, P. Jacques, P. Carron, R. Joos, J. Lenearts, L. Gosses, S. Pouplin, A. Ruyssen-Witrand, L. Sparsa, A. van Tubergen, D. van der Heijde, M. Dougados. Ann Rheum Dis. 2021; 80(11):1436-44.
Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis. S. Arends, F. Wink, J. Veneberg, R. Bos, E. van Roon, E. van der Veer, F. Maas, A. Spoorenberg. Br J Clin Pharmacol. 2020 Jun 12; 2021;87(2):644-51.
Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Molto, C. Lopez-Medina, F. van den Bosch, A. Boonen, C. Webers, E. Dernis, F. van Gaalen, M. Soubrier, P. Claudepierre, A. Baillet, M. Starsman-Kool, A. Spoorenberg, P. Jacques, P. Carron, R. Joos, J. Lenearts, L. Gosses, S. Pouplin, A. Ruyssen-Witrand, L. Sparsa, A. van Tubergen, D. van der Heijde, M. Dougados. Ann Rheum Dis. 2021; 80(11):1436-44.
Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis. S. Arends, F. Wink, J. Veneberg, R. Bos, E. van Roon, E. van der Veer, F. Maas, A. Spoorenberg. Br J Clin Pharmacol. 2020 Jun 12; 2021;87(2):644-51.
The IMPACT study: a clustered randomized controlled trial to assess the effect of a referral algorithm for axial spondyloarthritis. M. Jamal, A.M. Korver, M. Kuijper, D. Lopes Barreto, C.W.Y. Appels, A. Spoorenberg, B.W. Koes, J.M.W. Hazes, L.V. Hoeven, A.E.A.M. Weel. PLoS One. 2020;15(1):e0227025.
High prevalence of clinical spondyloarthritis features in patients with hidradenitis suppurativa. A. Rondags, K.R. van Straalen, S. Arends, H.H. van der Zee, E.P. Prens, A. Spoorenberg, B. Horváth. J Am Acad Dermatol. 2019;80(2)551-4.
High prevalence of hip involvement and decrease in inflammatory ultrasound lesions during TNF-α blocking therapy in patients with ankylosing spondylitis. F.R. Wink, S. Arends, F. Maas, H, Bootsma, E.N. Griep, G.A.W. Bruyn, A. Spoorenberg. Rheumatology. 2019;58(6):1040-6.
Although female patients with ankylosing spondylitis score worse on disease activity than male patients and improvement in disease activity is comparable, male patients show more radiographic progression during treatment with TNF-α inhibitors. B. van der Slik, A. Spoorenberg, F. Wink, R. Bos, H. Bootsma, F. Maas, S. Arends. Semin Arthritis Rheum 2019;48(5):828-33.
High prevalence of hidradenitis suppurativa symptoms in axial spondyloarthritis patients: A possible new extra-articular manifestation. A. Rondags, S. Arends, F.R. Wink, B. Horvath, A. Spoorenberg. Seminars Arthritis Rheum 2019 Feb;48(4):611-7.
High prevalence of clinical spondyloarthritis features in patients with hidradenitis suppurativa. Rondags A, van Straalen KR, Arends S, van der Zee HH, Prens EP, Spoorenberg A, Horváth B. J Am Acad Dermatol. 2018 Dec 13. [Epub ahead of print]
Uncovering the heterogeneity of disease impact in axial spondyloarthritis:bivariate trajectories of disease activity and quality of life. Imkamp M, Lima Passos V, Boonen A, Arends S, Dougados M, Landewé R, Ramiro S, Van den Bosch F, van der Heijde D, Wink FR, Spoorenberg A, van Tubergen A. RMD Open. 2018 Nov 14. eCollection 2018.
Although female patients with ankylosing spondylitis score worse on diseaseactivity than male patients and improvement in disease activity is comparable,male patients show more radiographic progression during treatment with TNF-αinhibitors. van der Slik B, Spoorenberg A, Wink F, Bos R, Bootsma H, Maas F, Arends S. Semin Arthritis Rheum. 2018 Aug 7. [Epub ahead of print]
Employment and the role of personal factors among patients with ankylosing spondylitis: a Dutch cross-sectional case-control study. Webers C, Vanhoof L, van Genderen S, Heuft L, van de Laar M, Luime J, van der Heijde D, van Gaalen FA, Spoorenberg A, Boonen A. RMD Open. 2018 Jun 27, eCollection 2018.
High prevalence of hidradenitis suppurativa symptoms in axial spondyloarthritis patients: A possible new extra-articular manifestation. Rondags A, Arends S, Wink FR, Horváth B, Spoorenberg A. Semin Arthritis Rheum. 2018 Mar 20. [Epub ahead of print]
Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-α inhibitors. Carbo MJG, Spoorenberg A, Maas F, Brouwer E, Bos R, Bootsma H, van der Veer E, Wink F, Arends S. PLoS One. 2018 Apr 24. eCollection 2018.
Reduction in Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Prolonged Treatment With Tumor Necrosis Factor Inhibitors. Maas F, Arends S, Brouwer E, Essers I, van der Veer E, Efde M, van Ooijen PMA, Wolf R, Veeger NJGM, Bootsma H, Wink FR, Spoorenberg A. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1011-1019.
Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-α inhibitors. F. Maas, S. Arends, F.R. Wink, R. Bos, H. Bootsma, E. Brouwer, A. Spoorenberg. PLOS One. 2017 Jun 22;12(6):e0177231.
Social role participation and satisfaction with life: A study among patients with ankylosing spondylitis and population controls. van Genderen S, Plasqui G, van der Heijde D, van Gaalen F, Heuft L, Luime J, Spoorenberg A, Arends S, Lacaille D, Gignac M, Landewé R, Boonen A. Arthritis Care Res (Hoboken). 2017 Jun 16. [Epub ahead of print]
Clinical Risk Factors for the Presence and Development of Vertebral Fractures in Patients With Ankylosing Spondylitis. Maas F, Spoorenberg A, van der Slik BPG, van der Veer E, Brouwer E, Bootsma H, Bos R, Wink FR, Arends S. Arthritis Care Res (Hoboken). 2017 May;69(5):694-702.
Ultrasound Evaluation of the Entheses in Daily Clinical Practice during Tumor Necrosis Factor-α Blocking Therapy in Patients with Ankylosing Spondylitis. Wink F, Bruyn GA, Maas F, Griep EN, van der Veer E, Bootsma H, Brouwer E, Arends S, Spoorenberg A. J Rheumatol. 2017 May;44(5):587-593.
Incorporating assessment of the cervical facet joints in the modified Stoke ankylosing spondylitis spine score is of additional value in the evaluation of spinal radiographic outcome in ankylosing spondylitis. Maas F, Arends S, Brouwer E, Bootsma H, Bos R, Wink FR, Spoorenberg A. Arthritis Res Ther. 2017 Apr 26;19(1):77.
Radiographic damage and progression of the cervical spine in ankylosing spondylitis patients treated with TNF-α inhibitors: Facet joints vs. vertebral bodies. Maas F, Spoorenberg A, Brouwer E, van der Veer E, Bootsma H, Bos R, Wink FR, Arends S. Semin Arthritis Rheum. 2017 Apr;46(5):562-568.
Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice. Arends S, Brouwer E, Efde M, van der Veer E, Bootsma H, Wink F, Spoorenberg A. Clin Exp Rheumatol. 2017 Jan-Feb;35(1):61-68.
Social Role Participation in Patients With Ankylosing Spondylitis: A Cross-Sectional Comparison With Population Controls. van Genderen S, Plasqui G, Landewé R, Lacaille D, Arends S, van Gaalen F, van der Heijde D, Heuft L, Luime J, Spoorenberg A, Gignac M, Boonen A. Arthritis Care Res (Hoboken). 2016 Dec;68(12):1899-1905.
Development and Validation of a Short Form of the Social Role Participation Questionnaire in Patients with Ankylosing Spondylitis. Oude Voshaar M, van Onna M, van Genderen S, van de Laar M, van der Heijde D, Heuft L, Spoorenberg A, Luime J, Gignac M, Boonen A. J Rheumatol. 2016 Jul;43(7):1386-92.
Radiographic vertebral fractures develop in patients with ankylosing spondylitis during 4 years of TNF-α blocking therapy. Maas F, Spoorenberg A, Brouwer E, Schilder AM, Chaudhry RN, Wink F, Bootsma H, van der Veer E, Arends S. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):191-9.
Social Role Participation Questionnaire for patients with ankylosing spondylitis: translation into Dutch, reliability and construct validity. van Genderen S, Plasqui G, Lacaille D, Arends S, van Gaalen F, van der Heijde D, Heuft L, Keszei A, Luime J, Spoorenberg A, Landewé R, Gignac M, Boonen A. RMD Open. 2016 Feb 1;2(1):e000177.
Obesity Is Common in Axial Spondyloarthritis and Is Associated with Poor Clinical Outcome. Maas F, Arends S, van der Veer E, Wink F, Efde M, Bootsma H, Brouwer E, Spoorenberg A. J Rheumatol. 2016 Feb;43(2):383-7.
Bechterew onderzoek in het UMCG en het MCL: het Groningen Leeuwarden Axiale Spondyloartritis (GLAS) cohort. Maas F. Verenigingsblad Reumapatiëntenvereniging (RPV) Groningen. 2016;2:18-20.
Accelerometer Quantification of Physical Activity and Activity Patterns in Patients with Ankylosing Spondylitis and Population Controls. van Genderen S, Boonen A, van der Heijde D, Heuft L, Luime J, Spoorenberg A, Arends S, Landewé R, Plasqui G. J Rheumatol. 2015 Dec;42(12):2369-75.
Male and female patients with axial spondyloarthritis experience disease activity, physical function and quality of life differently: results from the Groningen Leeuwarden Axial Spondyloarthritis cohort. Arends S, Maas F, Wink F, Efde M, Bootsma H, van der Veer E, Brouwer E, Spoorenberg A. Rheumatology (Oxford). 2015 Jul;54(7):1333-5.
Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-α blocking therapy: a prospectivelongitudinal observational cohort study. Maas F, Spoorenberg A, Brouwer E, Bos R, Efde M, Chaudhry RN, Veeger NJ, van Ooijen PM, Wolf R, Bootsma H, van der Veer E, Arends S. PLoS One. 2015 Apr 16;10(4):e0122693.
Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Arends S, van der Veer E, Kamps FB, Houtman PM, Bos R, Bootsma H, Brouwer E, Spoorenberg A. Clin Exp Rheumatol. 2015 Mar-Apr;33(2):174-80.
Higher bone turnover is related to spinal radiographic damage and low bone mineral density in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Arends S, Spoorenberg A, Efde M, Bos R, Leijsma MK, Bootsma H, Veeger NJ, Brouwer E, van der Veer E. PLoS One. 2014 Jun 11;9(6):e99685.
Clinical studies on bone-related outcome and the effect of TNF-α blocking therapy in ankylosing spondylitis. Arends S, Spoorenberg A, Brouwer E, van der Veer E. Curr Opin Rheumatol. 2014 May;26(3):259-68.
Daily physical activity in ankylosing spondylitis: validity and reliability of the IPAQ and SQUASH and the relation with clinicalassessments. Arends S, Hofman M, Kamsma YP, van der Veer E, Houtman PM, Kallenberg CG, Spoorenberg A, Brouwer E. Arthritis Res Ther. 2013 Aug 23;15(4):R99.
Validity and reliability of the Dutch adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) Questionnaire. Wink F, Arends S, McKenna SP, Houtman PM, Brouwer E, Spoorenberg A. PLoS One. 2013;8(2):e55912
Botmetabolisme en respons op anti-TNF behandeling bij de ziekte van Bechterew. S Arends. Osteoporose Journaal. 2012;Sep:13-7.
Baseline predictors of response to TNF-α blocking therapy in ankylosing spondylitis. Arends S, van der Veer E, Kallenberg CG, Brouwer E, Spoorenberg A. Curr Opin Rheumatol. 2012 May;24(3):290-8.
The effect of three years of TNFα blocking therapy on markers of bone turnover and their predictive value for treatmentdiscontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. Arends S, Spoorenberg A, Houtman PM, Leijsma MK, Bos R, Kallenberg CG, Groen H, Brouwer E, van der Veer E. Arthritis Res Ther. 2012 Apr 30;14(2):R98.
Bone turnover and predictors of response in ankylosing spondylitis. Arends S. Nederlands Tijdschrift voor Reumatologie. 2012;3:12-6.
Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A. Arthritis Res Ther. 2011 Jun 20;13(3):R94.
Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis. Arends S, van der Veer E, Groen H, Houtman PM, Jansen TL, Leijsma MK, Bijzet J, Limburg PC, Kallenberg CG, Spoorenberg A, Brouwer E. J Rheumatol. 2011 Aug;38(8):1644-50.
The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Arends S, Spoorenberg A, Bruyn GA, Houtman PM, Leijsma MK, Kallenberg CG, Brouwer E, van der Veer E. Osteoporos Int. 2011 May;22(5):1431-9.
The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosingspondylitis. Arends S, Lebbink HR, Spoorenberg A, Bungener LB, Roozendaal C, van der Veer E, Houtman PM, Griep EN, Limburg PC, Kallenberg CG, Wolbink GJ, Brouwer E. Clin Exp Rheumatol. 2010 Sep-Oct;28(5):661-8.
Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. de Vries MK, Brouwer E, van der Horst-Bruinsma IE, Spoorenberg A, van Denderen JC, Jamnitski A, Nurmohamed MT, Dijkmans BA, Aarden LA, Wolbink GJ. Ann Rheum Dis. 2009 Nov;68(11):1787-8.
